DBDemian Bellido

Demian Bellido

*This is an algorithmically generated author record based on publicly available information.

Demian Bellido has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Impact of the Implementation of a Bovine Viral Diarrhea Virus Targeted Vaccine in Dairy Farms: Longitudinal Analysis

    by Demian Bellido, Diego Wenz, Martin Schang, Facundo Tibaldo Rubiolo, Pablo Mangioni, Emanuel Gumina, Andrés Wigdorovitz, Viviana Parreño

    Objective: This study evaluated the effect of a novel subunit-targeted vaccine against BVDV in six dairy farms in Argentina. Methods: Reproductive, health, and production parameters—including conception and abortion rates, open days, calves born per insemination, as well as newborn and overall mortality, and milk production—were monitored over a ten-year period (2014–2023). Data were analyzed annually to assess trends and compare the periods before and after vaccine introduction. Results: All parameters showed significant improvement after vaccine incorporation, with an 11% increase in conception rate, a 5% reduction in abortion rate, a 12% increase in calves per insemination rate, and a decrease of 11 open days (8.4%). Additionally, newborn mortality and overall mortality decreased by 33% and 16%, respectively, while milk production increased by 9%. These data were also compared with eight non-vaccinated dairy farms, and significant differences were observed in health and reproductive parameters. Conclusions: These findings indicate that vaccination with an effective non-replicating subunit vaccine can successfully minimize the impact of BVDV in dairy farms.


  • Open Access

    Impact of the implementation of a Bovine Viral Diarrhea Virus vaccination program in dairy farms: Longitudinal analysis

    by Demian Bellido, Diego Wenz, Martin Schang, Facundo Tibaldo Rubiolo, Pablo Mangioni, Emanuel Gumina, Andrés Wigdorovitz, Viviana Parreño

    Bovine Viral Diarrhea Virus (BVDV) is one of the most prevalent pathogens in Argentinian herds affecting the performance of both beef cattle and dairy cattle. The traditional approach of removing PI cattle to control BVDV infections is not feasible to implement at large scale in our country due to geographical and productive characteristics. In this study we evaluated the effect of a novel subunit targeted vaccine against BVDV to reduce the impact of the virus in dairy herds. Different reproductive, health and productive parameters including conception and abortion rates, open days, calves born per insemination, newborn and overall mortality, and milk production were studied for a ten-year period (2014 – 2023) in six different dairy farms from three different provinces of Argentina. Data were analyzed annually to study the evolution trend of each index and means were compared between two periods: years before and years after vaccine introduction to the herds. All the parameters analyzed showed a significant improvement after the incorporation of the targeted vaccine. The obtained results showed that vaccination with an effective non-replicating vaccine can be a successful approach to minimize the impact of BVDV in dairy farms.

  • Open Access

    First evaluation of the impact of a targeted subunit vaccine against bovine viral diarrhea virus in feedlot cattle

    by Demian Bellido, Emanuel R Gumina, Gonzalo J Rodríguez Senes, Franco M Chiariotti, Maximiliano Audrito, Pedro M Sueldo, Gustavo M Sueldo, Andrés Wigdorovitz

    Bovine respiratory disease (BRD) is a serious health and economic problem in the beef industry, which is often associated with transportation and caused by different pathogens. In this study, we evaluated the effect of a novel subunit targeted vaccine against bovine viral diarrhea virus (BVDV) in feedlot cattle, a major viral agent of BRD. The core of this novel vaccine is the fusion of the BVDV structural glycoprotein, E2, to a single-chain antibody, APCH, together termed, APCH-E2. The APCH antibody targets the E2 antigen to the major histocompatibility type II molecule (MHC-II) present in antigen-presenting cells. To evaluate the vaccine, 2,992 animals were randomly allocated into two groups, control group (N = 1,491) and treatment group (N = 1,501). Animals of both groups received the routine sanitary plan: two doses of clostridial, respiratory, and rabies vaccines. Animals within the treatment group also received two doses of a targeted subunit vaccine against BVDV. Serum samples were taken on the day of the first inoculation (T0) and 90 d later (T90). Viral circulation was monitored using an anti-P80 ELISA (virus-specific) and immune response was evaluated by anti-E2 ELISA (detects virus and vaccine immune responses). Only animals treated for respiratory disease were considered positive cases of BRD. Results demonstrate that the control group had significantly more animals treated for BRD cases compared to the treatment group (5.9% vs. 3.7%, P = 0.02). The control group had a greater number of animals positive for anti-P80 antibodies and significantly fewer animals positive for anti-E2 antibodies compared to the treatment group (69% vs. 61% and 71% vs. 99%, respectively, P = 0.003), consistent with natural viral circulation within this group. The treatment group, conversely, had fewer animals positive for anti-P80 antibodies and a greater number of animals positive for anti-E2 antibodies, consistent with a robust vaccine-induced antibody response and a reduction of the BVDV circulation within this group. The data indicate the new subunit targeted vaccine induced greater anti-E2 antibodies and reduced the amount of BVD virus circulation within the treatment group leading to a fewer number of animals needing to be treated for BRD. Our objective was to evaluate the impact of a novel vaccine against bovine viral diarrhea virus (BVDV) in a commercial feedlot. This new vaccine directs the antigen to a subgroup of bovine white cells to increase the immune response against the BVDV virus. BVDV-induced immunosuppression weakens the defense of the infected bovines. In feedlot cattle, this immunosuppression leads to bovine respiratory disease (BRD). To test this novel vaccine, 2,992 animals were separated into two groups, control group (N = 1,491) and treatment group (N = 1,501). Animals in both groups received the routine sanitary plan, while animals within the treatment group also received two doses of the targeted subunit vaccine against BVDV. Animals within the treatment group showed less viral circulation and less BRD cases than the animals in the control group. These results indicate the new targeted vaccine is an effective tool to reduce BVDV viral circulation and prevent BRD in feedlot cattle.


  • A novel MHC‐II targeted BVDV subunit vaccine induces a neutralizing immunological response in guinea pigs and cattle

    by Demian Bellido, Josefina Baztarrica, Lucía Rocha, Andrea Pecora, Mario Acosta, José M. Escribano, Viviana Parreño, Andrés Wigdorovitz

    Bovine viral diarrhea virus (BVDV) is a major cause of economic loss in the cattle industry, worldwide. Infection results in reduced productive performance, growth retardation, reduced milk production, and increased susceptibility to other diseases leading to early culling of animals. There are two primary methods used to control the spread of BVDV: the elimination of persistently infected (PI) animals and vaccination. Currently, modified live or inactivated vaccines are used in BVDV vaccination programs, but there are safety risks or insufficient protection, respectively, with these vaccines. Here we report the development and efficacy of the first targeted subunit vaccine against BVDV. The core of the vaccine is the fusion of the BVDV structural protein, E2, to a single‐chain antibody, APCH, together termed, APCH‐E2. The APCH antibody targets the E2 antigen to the major histocompatibility type II molecule (MHC‐II) present on antigen‐presenting cells. Industrial production of the vaccine is carried out using the baculovirus expression vector system (BEVS) using single‐use manufacturing technologies. This new subunit vaccine induces strong BVDV‐specific neutralizing antibodies in guinea pigs and cattle. Importantly, in cattle with low levels of natural BVDV‐specific neutralizing antibodies, the vaccine induced strong neutralizing antibody levels to above the protective threshold, as determined by a competition ELISA. The APCH‐E2 vaccine induced a rapid and sustained neutralizing antibody response compared to a conventional vaccine in cattle.


  • Open Access

    Expression of the Multimeric and Highly Immunogenic Brucella spp. Lumazine Synthase Fused to Bovine Rotavirus VP8d as a Scaffold for Antigen Production in Tobacco Chloroplasts

    by E. Federico Alfano, Ezequiel M. Lentz, Demian Bellido, María J. Dus Santos, Fernando A. Goldbaum, Andrés Wigdorovitz, Fernando F. Bravo-Almonacid

    Lumazine synthase from Brucella spp. (BLS) is a highly immunogenic decameric protein which can accommodate foreign polypeptides or protein domains fused to its N-termini, markedly increasing their immunogenicity. The inner core domain (VP8d) of VP8 spike protein from bovine rotavirus (BRV) is responsible for viral adhesion to sialic acid residues and infection. It also displays neutralizing epitopes, making it a good candidate for vaccination. In this work, the BLS scaffold was assessed for the first time in plants for recombinant vaccine development by N-terminally fusing BLS to VP8d and expressing the resulting fusion (BLSVP8d) in tobacco chloroplasts. Transplastomic plants were obtained and characterized by Southern, northern and western blot. BLSVP8d was highly expressed, representing 40% of total soluble protein (TSP) (4.85 mg/g fresh tissue). BLSVP8d remained soluble and stable during all stages of plant development and even in lyophilized leaves stored at room temperature. Soluble protein extracts from fresh and lyophilized leaves were able to induce specific neutralizing IgY antibodies in a laying hen model. This work presents BLS as an interesting platform for highly immunogenic injectable, or even oral, subunit vaccines. Lyophilization of transplastomic leaves expressing stable antigenic fusions to BLS would further reduce costs and simplify downstream processing, purification and storage, allowing for more practical vaccines.


  • Open Access

    Development of an APC-targeted multivalent E2-based vaccine against Bovine Viral Diarrhea Virus types 1 and 2

    by A. Pecora, D.A. Malacari, M.S. Perez Aguirreburualde, D. Bellido, M.C. Nuñez, M.J. Dus Santos, J.M. Escribano, A. Wigdorovitz


  • Open Access

    Development of an enhanced bovine viral diarrhea virus subunit vaccine based on E2 glycoprotein fused to a single chain antibody which targets to antigen-presenting cells

    by Andrea Pecora, Darío A. Malacari, María S. Pérez Aguirreburualde, Demian Bellido, José M. Escribano, María J. Dus Santos, Andrés Wigdorovitz


  • Quantitation of cytokine gene expression by real time PCR in bovine milk and colostrum cells from cows immunized with a bovine rotavirus VP6 experimental vaccine

    by D.D. Gonzalez, A. Rimondi, M.S. Perez Aguirreburualde, M. Mozgovoj, D. Bellido, A. Wigdorovitz, M.J. Dus Santos


  • VP8* antigen produced in tobacco transplastomic plants confers protection against bovine rotavirus infection in a suckling mouse model

    by E.M. Lentz, M.V. Mozgovoj, D. Bellido, M.J. Dus Santos, A. Wigdorovitz, F.F. Bravo-Almonacid


  • Evaluation of a bovine rotavirus VP6 vaccine efficacy in the calf model of infection and disease

    by Diego Daniel Gonzalez, Marina Valeria Mozgovoj, Demian Bellido, Daniela Vanesa Rodriguez, Fernando María Fernandez, Andrés Wigdorovitz, Viviana Gladys Parreño, María José Dus Santos